

Standards for federally sponsored international clinical research— An introduction

Christine Grady RN, PhD


Department of Bioethics, NIH CC

The views presented are mine and do not necessarily represent those of the National Institutes of Health, Public Health Service, or the Department of Health and Human Services

Standards for U.S. federally sponsored international clinical research

- The Common Rule
- U.S. FDA regulations/ GCP and ICH/GCP
- Clinicaltrials.gov
- Agency specific policies and guidance
- Legal and ethical requirements of collaborating and host jurisdiction(s)
- International guidance, e.g. CIOMS, Helsinki, and others

Standards for U.S. federally sponsored international clinical research



The U.S. Common Rule

- Federal Policy for the Protection of Human Subjects
- Currently followed by 17 federal agencies*
 - e.g. DHHS- 45CFR Part 46; VA – 38 CFR Part 16; USAID -- 24 CFR Part 60, others

U.S. Common Rule-DHHS

- Title 45 US CFR.46

- Subpart A- Basic DHHS Policy for Protection of Human Research Subjects
- Subpart B- Pregnant women, human fetuses, and neonates
- Subpart C- Prisoners
- Subpart D- Children
- Subpart E- IRB Registration



45CFR.46 Protection of Human Subjects

(Subpart A, Common Rule)

- Two “pillars” of human subjects protection:
- Independent review
 - Composition and function of a local institutional review board (IRB)
- Informed consent
 - Basic elements, documentation requirements, waiver criteria

45CFR.46 Protection of Human Subjects (Subpart A, Common Rule)

- Criteria for IRB approval of research (45CFR.46.111)
 - **Risks are minimized**, consistent with sound research design
 - **Risks are reasonable** in relation to expected benefits, if any, and the importance of the knowledge reasonably expected
 - **Subject selection is equitable**, and
 - **Informed consent** will be sought from each subject or LAR and appropriately documented.
 - Adequate provisions for **monitoring**
 - Adequate provisions for protecting **privacy and confidentiality**
 - Additional protections for subjects likely to be **vulnerable** to coercion or undue influence

Assurance of Compliance with Federal Common Rule

- Office of Human Research Protections (OHRP) <http://www.hhs.gov/ohrp>
- Federal Wide Assurance (FWA)
- Documents institutional commitment to comply with the Common Rule

FDA REGULATIONS-Protection of Human Subjects

- 21CFR.50 Protection of Human Subjects (informed consent)
- 21CFR.56 Institutional Review Boards
- Other related FDA regulations, e.g.
 - 21CFR.312 Investigational New Drug Application
 - 21CFR.812 Investigational Device Exemption

<http://www.fda.gov/oc/gcp/regulations.html>



FDA and International Conference on Harmonization/Good Clinical Practice Guidelines

- Good Clinical Practice: Consolidated Guideline (1997) of the International Conference on Harmonisation (E6-(R1) - ICH/GCP
"...an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve the participation of human subjects"
- Goals: Harmonize technical procedures and standards; improve quality; speed time to market
- FDA endorsed ICH/GCP in 1997
- ICH guidelines have been adopted into law in several countries (the 'de facto' global standard)
- Used as guidance for the FDA in the form of GCP



Standards for US supported research

- Registration in ClinicalTrials.gov
- FDA Amendments Act of 2007 or FDAAA, Title VIII, Section 801 mandates that a "responsible party" ...register and report results of certain "applicable clinical trials"

Standards: Agency specific guidance; e.g. NIH

- NIH guidelines on the inclusion of women and minorities
- NIH Guidelines on the Inclusion of Children
- Data and Safety Monitoring Plans


<http://grants.nih.gov/grants/policy/policy.htm>



International Guidance

- National regulations and laws in collaborating jurisdictions
- Nuremberg Code
- Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects, World Medical Association
- International Ethical Guidelines for Biomedical Research Involving Human Subjects, Council for International Organizations of Medical Sciences CIOMS/WHO
- Universal Declaration on Bioethics and Human Rights, UNESCO

Standards for protection of research subjects



Standards: Current challenges

- Harmonization
- Burden
- Effectiveness
- Collaboration and respect

Current challenges: Harmonization

- Different content
 - e.g. waiver of consent; compensation for injury
- Different purview
 - e.g. US supported research, investigation of FDA regulated products, guidance
- Divergent interpretations
 - e.g. undue inducement, minimal risk, responsiveness, etc

Current challenges: Burden

- The number of rules and guidelines
- Disincentive to do clinical research or incentive to seek least burdensome path
- Delay
- Hinder otherwise ethically appropriate research?

Current challenges: Effectiveness

- Rules alone cannot protect research participants
Need quality science, responsible engaged researchers and teams, carefully applied ethical principles, engagement of participants and communities...
- “The mere formulation of ethical guidelines for ...research involving human subjects will hardly resolve all moral doubts that can arise...” CIOMS 2002

Current challenges: Effectiveness

- Insufficient guidance re: critical and complex issues (and disagreement)
 - E.g. Relevance of background conditions and injustices, what is owed to participants and to communities, etc.
- Inconsistencies in implementation

Current challenges: Collaboration and respect

- Collaboration
- Equivalent protections
- Capacity development
- Community engagement

- Ethical responsibility to protect the rights and welfare of research participants and communities in research



- Ethical responsibility to advance the good of societies, communities, and research participants through research